Neuropilin-1 blockade with optimized nanobody formats as novel cancer therapy

Immunotherapy has meant a breakthrough in the treatment of some cancers. However, the majority of patients remain unresponsive and multipce cancer types are refractory to immunotherapy. Hence, novel approaches are needed to bridge the gap in response rates. Neuropilin-1 (NRP1) is often overexpressed within tumors and correlates with a worse prognosis, likely due to its immune suppressive caoacity.